• Lattice Medical

  Participated · Series B · Oct 2025

  Lattice Medical develops resorbable, 3D-printed implantable devices for reconstruction of soft tissues such as in post-cancer breast and deep subcutaneous tissue reconstruction. The company plans to integrate a supercritical CO2 sterilization process into its industrial 3D-printing manufacturing chain to meet implantable-device sterility requirements while preserving material properties. It also intends to shorten production times, reinforce regulatory control, secure critical manufacturing steps, and offer sterilization services to third parties. Founded in 2017 by Julien Payen, the company holds 14 international patents. Financially, Lattice Medical raised approximately €2.15 million for the MEDCO2 project and previously completed a €43 million funding round in 2025. Clinically, it closed the first phase of its TIDE trial with 10 patients enrolled.

No current team members are available.